Consensus paper of the WFSBP Task Force on Biological Markers: Criteria for biomarkers and endophenotypes of schizophrenia part II: Cognition, neuroimaging and genetics

References

• Addington J, Barbato M. 2012. The role of cognitive functioning in the outcome of those at clinical high risk for developing psychosis. Epidemiol Psychiatr Sci. 21:335–342.
   PubMed Web of Science ®Google Scholar
• Allen AJ, Griss ME, Folley BS, Hawkins KA, Pearlson GD. 2009. Endophenotypes in schizophrenia: a selective review. Schizophr Res. 109:24–37.
   PubMed Web of Science ®Google Scholar
• APA. 2013. Diagnostic and statistical manual of mental disorders. Arlington (VA): American Psychiatric Association.
   Google Scholar
• Arakawa R, Ichimiya T, Ito H, Takano A, Okumura M, Takahashi H, Takano H, Yasuno F, Kato M, Okubo Y, et al. 2009. Increase in thalamic binding of [(11)C]PE2I in patients with schizophrenia: a positron emission tomography study of dopamine transporter. J Psychiat Res. 43:1219–1223.
   PubMed Web of Science ®Google Scholar
• Arfken CL, Carney S, Boutros NN. 2009. Translating biological parameters into clinically useful diagnostic tests. Curr Psychiatry Rep. 11:320–323.
   PubMed Web of Science ®Google Scholar
• Atluri G, Padmanabhan K, Fang G, Steinbach M, Petrella JR, Lim K, Macdonald A, 3rd, Samatova NF, Doraiswamy PM, Kumar V. 2013. Complex biomarker discovery in neuroimaging data: finding a needle in a haystack. Neuroimage Clin. 3:123–131.
   PubMed Web of Science ®Google Scholar
• Bae JS, Pasaje CF, Park BL, Cheong HS, Kim JH, Kim JY, Shin JG, Park CS, Kim BJ, Lee CS, et al. 2012. Genetic association analysis of ERBB4 polymorphisms with the risk of schizophrenia and SPEM abnormality in a Korean population. Brain Res. 1466:146–151.
   PubMed Web of Science ®Google Scholar
• Bakkour N, Samp J, Akhras K, El Hammi E, Soussi I, Zahra F, Duru G, Kooli A, Toumi M. 2014. Systematic review of appropriate cognitive assessment instruments used in clinical trials of schizophrenia, major depressive disorder and bipolar disorder. Psychiatry Res. 216:291–302.
   PubMed Web of Science ®Google Scholar
• Barkus C, Sanderson DJ, Rawlins JN, Walton ME, Harrison PJ, Bannerman DM. 2014. What causes aberrant salience in schizophrenia? A role for impaired short-term habituation and the GRIA1 (GluA1) AMPA receptor subunit. Mol Psychiatry. 19:1060–1070.
   PubMed Web of Science ®Google Scholar
• Beckmann H. 1999. Editor’s comment. In: Leonhard K, editor. Classification of endogenous psychoses and their differentiated etiology. 2nd, revised and enlarged ed. Wien, New York: Springer.
   Google Scholar
• Bendikov I, Nadri C, Amar S, Panizzutti R, De Miranda J, Wolosker H, Agam G. 2007. A CSF and postmortem brain study of D-serine metabolic parameters in schizophrenia. Schizophr Res. 90:41–51.
   PubMed Web of Science ®Google Scholar
• Berk M, Copolov D, Dean O, Lu K, Jeavons S, Schapkaitz I, Anderson-Hunt M, Judd F, Katz F, Katz P, et al. 2008. N-acetyl cysteine as a glutathione precursor for schizophrenia-a double-blind, randomized, placebo-controlled trial. Biol Psychiatry. 64:361–368.
   PubMed Web of Science ®Google Scholar
• Bernard JA, Mittal VA. 2014. Cerebellar-motor dysfunction in schizophrenia and psychosis-risk: the importance of regional cerebellar analysis approaches. Front Psychiatry. 5:160. doi:10.3389/fpsyt.2014.00160.
   PubMed Web of Science ®Google Scholar
• Bose SK, Turkheimer FE, Howes OD, Mehta MA, Cunliffe R, Stokes PR, Grasby PM. 2008. Classification of schizophrenic patients and healthy controls using [18F] fluorodopa PET imaging. Schizophr Res. 106:148–155.
   PubMed Web of Science ®Google Scholar
• Breier A, Su TP, Saunders R, Carson RE, Kolachana BS, de Bartolomeis A, Weinberger DR, Weisenfeld N, Malhotra AK, Eckelman WC, et al. 1997. Schizophrenia is associated with elevated amphetamine-induced synaptic dopamine concentrations: evidence from a novel positron emission tomography method. Proc Natl Acad Sci USA. 94:2569–2574.
   PubMed Web of Science ®Google Scholar
• Brunelin J, d’Amato T, Van Os J, Costes N, Suaud Chagny MF, Saoud M. 2010. Increased left striatal dopamine transmission in unaffected siblings of schizophrenia patients in response to acute metabolic stress. Psychiatry Res. 181:130–135.
   PubMed Web of Science ®Google Scholar
• Buchsbaum MS, Christian BT, Lehrer DS, Narayanan TK, Shi B, Mantil J, Kemether E, Oakes TR, Mukherjee J. 2006. D2/D3 dopamine receptor binding with [F-18]fallypride in thalamus and cortex of patients with schizophrenia. Schizophr Res. 85:232–244.
   PubMed Web of Science ®Google Scholar
• Buckner RL, Andrews-Hanna JR, Schacter DL. 2008. The brain's default network: anatomy, function, and relevance to disease. Ann N Y Acad Sci. 1124:1–38.
   PubMed Web of Science ®Google Scholar
• Cabranes JA, Ancin I, Santos JL, Sanchez-Morla E, Garcia-Jimenez MA, Lopez-Ibor JJ, Barabash A. 2013. No effect of polymorphisms in the non-duplicated region of the CHRNA7 gene on sensory gating P50 ratios in patients with schizophrenia and bipolar disorder. Psychiatry Res. 205:276–278.
   PubMed Web of Science ®Google Scholar
• Canuso CM, Pandina G. 2007. Gender and schizophrenia. Psychopharmacol Bull. 40:178–190.
   PubMed Web of Science ®Google Scholar
• Caravaggio F, Nakajima S, Borlido C, Remington G, Gerretsen P, Wilson A, Houle S, Menon M, Mamo D, Graff-Guerrero A. 2014. Estimating endogenous dopamine levels at D2 and D3 receptors in humans using the agonist radiotracer [(11)C]-(+)-PHNO. Neuropsychopharmacol. 39:2769–2776.
   PubMed Web of Science ®Google Scholar
• Cardno AG, Gottesman II. 2000. Twin studies of schizophrenia: from bow-and-arrow concordances to star wars Mx and functional genomics. Am J Med Genet. 97:12–17.
   PubMed Web of Science ®Google Scholar
• Cheong HS, Park BL, Kim EM, Park CS, Sohn JW, Kim BJ, Kim JW, Kim KH, Shin TM, Choi IG, et al. 2011. Association of RANBP1 haplotype with smooth pursuit eye movement abnormality. Am J Med Genet B Neuropsychiatr Genet. 156B:67–71.
   PubMed Web of Science ®Google Scholar
• Cocchi L, Harding IH, Lord A, Pantelis C, Yucel M, Zalesky A. 2014. Disruption of structure-function coupling in the schizophrenia connectome. Neuroimage Clin. 4:779–787.
   PubMed Web of Science ®Google Scholar
• Cropley VL, Innis RB, Nathan PJ, Brown AK, Sangare JL, Lerner A, Ryu YH, Sprague KE, Pike VW, Fujita M. 2008. Small effect of dopamine release and no effect of dopamine depletion on [18F]fallypride binding in healthy humans. Synapse. 62:399–408.
   PubMed Web of Science ®Google Scholar
• Cross-Disorder Group of the Psychiatric Genomics C, Lee SH, Ripke S, Neale BM, Faraone SV, Purcell SM, Perlis RH, Mowry BJ, Thapar A, Goddard ME, et al. 2013. Genetic relationship between five psychiatric disorders estimated from genome-wide SNPs. Nat Genet. 45:984–994.
   PubMed Web of Science ®Google Scholar
• Davatzikos C, Resnick SM, Wu X, Parmpi P, Clark CM. 2008. Individual patient diagnosis of AD and FTD via high-dimensional pattern classification of MRI. Neuroimage. 41:1220–1227.
   PubMed Web of Science ®Google Scholar
• de la Fuente-Sandoval C, Leon-Ortiz P, Favila R, Stephano S, Mamo D, Ramirez-Bermudez J, Graff-Guerrero A. 2011. Higher levels of glutamate in the associative-striatum of subjects with prodromal symptoms of schizophrenia and patients with first-episode psychosis. Neuropsychopharmacology. 36:1781–1791.
   PubMed Web of Science ®Google Scholar
• de la Fuente-Sandoval C, Reyes-Madrigal F, Mao X, Leon-Ortiz P, Rodriguez-Mayoral O, Solis-Vivanco R, Favila R, Graff-Guerrero A, Shungu DC. 2015. Cortico-Striatal GABAergic and glutamatergic dysregulations in subjects at ultra-high risk for psychosis investigated with proton magnetic resonance spectroscopy. Int J Neuropsychopharmacol. 19(3):pyv105. doi:10.1093/ijnp/pyv105.
   PubMed Web of Science ®Google Scholar
• Del Re EC, Bergen SE, Mesholam-Gately RI, Niznikiewicz MA, Goldstein JM, Woo TU, Shenton ME, Seidman LJ, McCarley RW, Petryshen TL. 2014. Analysis of schizophrenia-related genes and electrophysiological measures reveals ZNF804A association with amplitude of P300b elicited by novel sounds. Transl Psychiatry. 4:e346.
   PubMed Web of Science ®Google Scholar
• Derntl B, Habel U. 2011. Deficits in social cognition: a marker for psychiatric disorders? Eur Arch Psychiatry Clin Neurosci. 261:S145–S149.
   PubMed Web of Science ®Google Scholar
• Di X, Chan RC, Gong QY. 2009. White matter reduction in patients with schizophrenia as revealed by voxel-based morphometry: an activation likelihood estimation meta-analysis. Prog Neuropsychopharmacol Biol Psychiatry. 33:1390–1394.
   PubMed Web of Science ®Google Scholar
• Dickinson D, Ramsey ME, Gold JM. 2007. Overlooking the obvious: a meta-analytic comparison of digit symbol coding tasks and other cognitive measures in schizophrenia. Arch Gen Psychiatry. 64:532–542.
   PubMed Web of Science ®Google Scholar
• Dickson H, Cullen AE, Reichenberg A, Hodgins S, Campbell DD, Morris RG, Laurens KR. 2014. Cognitive impairment among children at-risk for schizophrenia. J Psychiatr Res. 50:92–99.
   PubMed Web of Science ®Google Scholar
• Do KQ, Trabesinger AH, Kirsten-Kruger M, Lauer CJ, Dydak U, Hell D, Holsboer F, Boesiger P, Cuenod M. 2000. Schizophrenia: glutathione deficit in cerebrospinal fluid and prefrontal cortex in vivo. Eur J Neurosci. 12:3721–3728.
   PubMed Web of Science ®Google Scholar
• Dominguez Mde G, Viechtbauer W, Simons CJ, van Os J, Krabbendam L. 2009. Are psychotic psychopathology and neurocognition orthogonal? A systematic review of their associations. Psychol Bull. 135:157–171.
   PubMed Web of Science ®Google Scholar
• Edwards AC, Bigdeli TB, Docherty AR, Bacanu S, Lee D, de Candia TR, Moscati A, Thiselton DL, Maher BS, Wormley BK, et al. 2015. Meta-analysis of positive and negative symptoms reveals schizophrenia modifier genes. Schizophr Bull. 42:279–287.
   PubMed Web of Science ®Google Scholar
• Ellison-Wright I, Bullmore E. 2009. Meta-analysis of diffusion tensor imaging studies in schizophrenia. Schizophr Res. 108:3–10.
   PubMed Web of Science ®Google Scholar
• Errico F, Napolitano F, Squillace M, Vitucci D, Blasi G, de Bartolomeis A, Bertolino A, D’Aniello A, Usiello A. 2013. Decreased levels of D-aspartate and NMDA in the prefrontal cortex and striatum of patients with schizophrenia. J Psychiatr Res. 47:1432–1437.
   PubMed Web of Science ®Google Scholar
• Erritzoe D, Rasmussen H, Kristiansen KT, Frokjaer VG, Haugbol S, Pinborg L, Baare W, Svarer C, Madsen J, Lublin H, et al. 2008. Cortical and subcortical 5-HT2A receptor binding in neuroleptic-naive first-episode schizophrenic patients. Neuropsychopharmacol. 33:2435–2441.
   PubMed Web of Science ®Google Scholar
• Falkai P. 2011. A desperate search for biomarkers in schizophrenia. What is going wrong? World Psychiatry. 10:38–39.
   PubMed Web of Science ®Google Scholar
• Farde L, Hall H, Ehrin E, Sedvall G. 1986. Quantitative analysis of D2 dopamine receptor binding in the living human brain by PET. Science. 231:258–261.
   PubMed Web of Science ®Google Scholar
• Ferrarelli F. 2013. Endophenotypes and biological markers of schizophrenia: from biological signs of illness to novel treatment targets. Curr Pharm Design. 19:6462–6479.
   PubMed Web of Science ®Google Scholar
• Fett AK, Viechtbauer W, Dominguez MD, Penn DL, van Os J, Krabbendam L. 2011. The relationship between neurocognition and social cognition with functional outcomes in schizophrenia: a meta-analysis. Neurosci Biobehav Rev. 35:573–588.
   PubMed Web of Science ®Google Scholar
• Frankle WG, Lombardo I, Kegeles LS, Slifstein M, Martin JH, Huang Y, Hwang DR, Reich E, Cangiano C, Gil R, et al. 2006. Serotonin 1A receptor availability in patients with schizophrenia and schizo-affective disorder: a positron emission tomography imaging study with [11C]WAY 100635. Psychopharmacology. 189:155–164.
   PubMed Web of Science ®Google Scholar
• Franzek E, Beckmann H. 1998. Different genetic background of schizophrenia spectrum psychoses: a twin study. Am J Psychiatry. 155:76–83.
   PubMed Web of Science ®Google Scholar
• Fromer M, Pocklington AJ, Kavanagh DH, Williams HJ, Dwyer S, Gormley P, Georgieva L, Rees E, Palta P, Ruderfer DM, et al. 2014. De novo mutations in schizophrenia implicate synaptic networks. Nature. 506:179–184.
   PubMed Web of Science ®Google Scholar
• Fujiwara H, Yassin W, Murai T. 2015. Neuroimaging studies of social cognition in schizophrenia. Psychiatry Clin Neurosci. 69:259–267.
   PubMed Web of Science ®Google Scholar
• Fusar-Poli P, Deste G, Smieskova R, Barlati S, Yung AR, Howes O, Stieglitz RD, Vita A, McGuire P, Borgwardt S. 2012. Cognitive functioning in prodromal psychosis: a meta-analysis. Arch Gen Psychiatry. 69:562–571.
   PubMed Web of Science ®Google Scholar
• Fusar-Poli P, Meyer-Lindenberg A. 2013a. Striatal presynaptic dopamine in schizophrenia, Part I: meta-analysis of dopamine active transporter (DAT) density. Schizophr Bull. 39:22–32.
   PubMed Web of Science ®Google Scholar
• Fusar-Poli P, Meyer-Lindenberg A. 2013b. Striatal presynaptic dopamine in schizophrenia, part II: meta-analysis of [(18)F/(11)C]-DOPA PET studies. Schizophr Bull. 39:33–42.
   PubMed Web of Science ®Google Scholar
• Gallinat J, Bajbouj M, Sander T, Schlattmann P, Xu K, Ferro EF, Goldman D, Winterer G. 2003. Association of the G1947A COMT (Val(108/158)Met) gene polymorphism with prefrontal P300 during information processing. Biol Psychiatry. 54:40–48.
   PubMed Web of Science ®Google Scholar
• Ghose S, Gleason KA, Potts BW, Lewis-Amezcua K, Tamminga CA. 2009. Differential expression of metabotropic glutamate receptors 2 and 3 in schizophrenia: a mechanism for antipsychotic drug action? Am J Psychiatry. 166:812–820.
   PubMed Web of Science ®Google Scholar
• Ginovart N. 2005. Imaging the dopamine system with in vivo [11C]raclopride displacement studies: understanding the true mechanism. Mol Imaging Biol. 7:45–52.
   PubMed Web of Science ®Google Scholar
• Girard SL, Gauthier J, Noreau A, Xiong L, Zhou S, Jouan L, Dionne-Laporte A, Spiegelman D, Henrion E, Diallo O, et al. 2011. Increased exonic de novo mutation rate in individuals with schizophrenia. Nat Genet. 43:860–863.
   PubMed Web of Science ®Google Scholar
• Glahn DC, Knowles EE, McKay DR, Sprooten E, Raventos H, Blangero J, Gottesman II, Almasy L. 2014. Arguments for the sake of endophenotypes: examining common misconceptions about the use of endophenotypes in psychiatric genetics. Am J Med Genet B Neuropsychiatr Genet. 165B:122–130.
   PubMed Web of Science ®Google Scholar
• Golimbet V, Gritsenko I, Alfimova M, Lebedeva I, Lezheiko T, Abramova L, Kaleda V, Ebstein R. 2006. Association study of COMT gene Val158Met polymorphism with auditory P300 and performance on neurocognitive tests in patients with schizophrenia and their relatives. World J Biol Psychiatry. 7:238–245.
   PubMed Web of Science ®Google Scholar
• Gottesman II, Gould TD. 2003. The endophenotype concept in psychiatry: etymology and strategic intentions. Am J Psychiatry. 160:636–645.
   PubMed Web of Science ®Google Scholar
• Grayton HM, Fernandes C, Rujescu D, Collier DA. 2012. Copy number variations in neurodevelopmental disorders. Prog Neurobiol. 99:81–91.
   PubMed Web of Science ®Google Scholar
• Green MF, Nuechterlein KH, Gold JM, Barch DM, Cohen J, Essock S, Fenton WS, Frese F, Goldberg TE, Heaton RK, et al. 2004. Approaching a consensus cognitive battery for clinical trials in schizophrenia: the NIMH-MATRICS conference to select cognitive domains and test criteria. Biol Psychiatry. 56:301–307.
   PubMed Web of Science ®Google Scholar
• Greicius M. 2008. Resting-state functional connectivity in neuropsychiatric disorders. Curr Opin Neurol. 21:424–430.
   PubMed Web of Science ®Google Scholar
• Grotegerd D, Stuhrmann A, Kugel H, Schmidt S, Redlich R, Zwanzger P, Rauch AV, Heindel W, Zwitserlood P, Arolt V, et al. 2014. Amygdala excitability to subliminally presented emotional faces distinguishes unipolar and bipolar depression: an fMRI and pattern classification study. Hum Brain Mapp. 35:2995–3007.
   PubMed Web of Science ®Google Scholar
• Grozeva D, Conrad DF, Barnes CP, Hurles M, Owen MJ, O’Donovan MC, Craddock N, Kirov G, WTCCC. 2012. Independent estimation of the frequency of rare CNVs in the UK population confirms their role in schizophrenia. Schizophr Res. 135:1–7.
   PubMed Web of Science ®Google Scholar
• Guha S, Rees E, Darvasi A, Ivanov D, Ikeda M, Bergen SE, Magnusson PK, Cormican P, Morris D, Gill M, et al. 2013. Implication of a rare deletion at distal 16p11.2 in schizophrenia. JAMA Psychiatry. 70:253–260.
   PubMed Web of Science ®Google Scholar
• Gulsuner S, Walsh T, Watts AC, Lee MK, Thornton AM, Casadei S, Rippey C, Shahin H, Consortium on the Genetics of S, Group PS, et al. 2013. Spatial and temporal mapping of de novo mutations in schizophrenia to a fetal prefrontal cortical network. Cell. 154:518–529.
   PubMed Web of Science ®Google Scholar
• Gusev A, Lee SH, Trynka G, Finucane H, Vilhjalmsson BJ, Xu H, Zang C, Ripke S, Bulik-Sullivan B, Stahl E, et al. 2014. Partitioning heritability of regulatory and cell-type-specific variants across 11 common diseases. Am J Hum Genet. 95:535–552.
   PubMed Web of Science ®Google Scholar
• Haijma SV, Van Haren N, Cahn W, Koolschijn PC, Hulshoff Pol HE, Kahn RS. 2013. Brain volumes in schizophrenia: a meta-analysis in over 18 000 subjects. Schizophr Bull. 39:1129–1137.
   PubMed Web of Science ®Google Scholar
• Haraldsson HM, Ettinger U, Magnusdottir BB, Ingason A, Hutton SB, Sigmundsson T, Sigurdsson E, Petursson H. 2010a. Neuregulin-1 genotypes and eye movements in schizophrenia. Eur Arch Psychiatry Clin Neurosci. 260:77–85.
   PubMed Web of Science ®Google Scholar
• Haraldsson HM, Ettinger U, Magnusdottir BB, Sigmundsson T, Sigurdsson E, Ingason A, Petursson H. 2009. COMT val(158)met genotype and smooth pursuit eye movements in schizophrenia. Psychiatry Res. 169:173–175.
   PubMed Web of Science ®Google Scholar
• Haraldsson HM, Ettinger U, Magnusdottir BB, Sigmundsson T, Sigurdsson E, Ingason A, Petursson H. 2010b. Catechol-O-methyltransferase Val 158 Met polymorphism and antisaccade eye movements in schizophrenia. Schizophr Bull. 36:157–164.
   PubMed Web of Science ®Google Scholar
• Harvey PD. 2014. What is the evidence for changes in cognition and functioning over the lifespan in patients with schizophrenia? J Clin Psychiatry. 75:34–38.
   PubMed Web of Science ®Google Scholar
• Hashimoto K. 2014a. Abnormalities of the glutamine-glutamate-GABA cycle in the schizophrenia brain. Schizophr Res. 156:281–282.
   PubMed Web of Science ®Google Scholar
• Hashimoto K. 2014b. Targeting of NMDA receptors in new treatments for schizophrenia. Expert Opin Ther Targets. 18:1049–1063.
   PubMed Web of Science ®Google Scholar
• Hashimoto K, Engberg G, Shimizu E, Nordin C, Lindstrom LH, Iyo M. 2005a. Elevated glutamine/glutamate ratio in cerebrospinal fluid of first episode and drug naive schizophrenic patients. BMC Psychiatry. 5:6.
   PubMed Web of Science ®Google Scholar
• Hashimoto K, Engberg G, Shimizu E, Nordin C, Lindstrom LH, Iyo M. 2005b. Reduced D-serine to total serine ratio in the cerebrospinal fluid of drug naive schizophrenic patients. Prog Neuropsychopharmacol Biol Psychiatry. 29:767–769.
   PubMed Web of Science ®Google Scholar
• Hashimoto K, Fukushima T, Shimizu E, Komatsu N, Watanabe H, Shinoda N, Nakazato M, Kumakiri C, Okada S, Hasegawa H, et al. 2003. Decreased serum levels of D-serine in patients with schizophrenia: evidence in support of the N-methyl-D-aspartate receptor hypofunction hypothesis of schizophrenia. Arch Gen Psychiatry. 60:572–576.
   PubMed Web of Science ®Google Scholar
• Hashimoto K, Malchow B, Falkai P, Schmitt A. 2013. Glutamate modulators as potential therapeutic drugs in schizophrenia and affective disorders. Eur Arch Psychiatry Clin Neurosci. 263:367–377.
   PubMed Web of Science ®Google Scholar
• Hietala J, Syvalahti E, Vilkman H, Vuorio K, Rakkolainen V, Bergman J, Haaparanta M, Solin O, Kuoppamaki M, Eronen E, et al. 1999. Depressive symptoms and presynaptic dopamine function in neuroleptic-naive schizophrenia. Schizophr Res. 35:41–50.
   PubMed Web of Science ®Google Scholar
• Hietala J, Syvalahti E, Vuorio K, Rakkolainen V, Bergman J, Haaparanta M, Solin O, Kuoppamaki M, Kirvela O, Ruotsalainen U, et al. 1995. Presynaptic dopamine function in striatum of neuroleptic-naive schizophrenic patients. Lancet. 346:1130–1131.
   PubMed Web of Science ®Google Scholar
• Hirvonen J, van Erp TG, Huttunen J, Aalto S, Nagren K, Huttunen M, Lonnqvist J, Kaprio J, Hietala J, Cannon TD. 2005. Increased caudate dopamine D2 receptor availability as a genetic marker for schizophrenia. Arch Gen Psychiatry. 62:371–378.
   PubMed Web of Science ®Google Scholar
• Howes OD, Montgomery AJ, Asselin MC, Murray RM, Valli I, Tabraham P, Bramon-Bosch E, Valmaggia L, Johns L, Broome M, et al. 2009. Elevated striatal dopamine function linked to prodromal signs of schizophrenia. Arch Gen Psychiatry. 66:13–20.
   PubMed Web of Science ®Google Scholar
• Hurlemann R, Matusch A, Kuhn KU, Berning J, Elmenhorst D, Winz O, Kolsch H, Zilles K, Wagner M, Maier W, et al. 2008. 5-HT2A receptor density is decreased in the at-risk mental state. Psychopharmacology (Berl.). 195:579–590.
   PubMed Web of Science ®Google Scholar
• Ingason A, Kirov G, Giegling I, Hansen T, Isles AR, Jakobsen KD, Kristinsson KT, le Roux L, Gustafsson O, Craddock N, et al. 2011a. Maternally derived microduplications at 15q11-q13: implication of imprinted genes in psychotic illness. Am J Psychiatry. 168:408–417.
   PubMed Web of Science ®Google Scholar
• Ingason A, Rujescu D, Cichon S, Sigurdsson E, Sigmundsson T, Pietilainen OP, Buizer-Voskamp JE, Strengman E, Francks C, Muglia P, et al. 2011b. Copy number variations of chromosome 16p13.1 region associated with schizophrenia. Mol Psychiatry. 16:17–25.
   PubMed Web of Science ®Google Scholar
• International Schizophrenia Consortium. 2008. Rare chromosomal deletions and duplications increase risk of schizophrenia. Nature. 455:237–241.
   PubMed Web of Science ®Google Scholar
• International Schizophrenia Consortium; Purcell SM, Wray NR, Stone JL, Visscher PM, O’Donovan MC, Sullivan PF, Sklar P. International Schizophrenia Consortium. 2009. Common polygenic variation contributes to risk of schizophrenia and bipolar disorder. Nature. 460:748–752.
   PubMed Web of Science ®Google Scholar
• Jacquet H, Raux G, Thibaut F, Hecketsweiler B, Houy E, Demilly C, Haouzir S, Allio G, Fouldrin G, Drouin V, et al. 2002. PRODH mutations and hyperprolinemia in a subset of schizophrenic patients. Hum Mol Genet. 11:2243–2249.
   PubMed Web of Science ®Google Scholar
• Kalia M, Costa ESJ. 2015. Biomarkers of psychiatric diseases: current status and future prospects. Metab Clin Exp. 64:S11–S15.
   PubMed Web of Science ®Google Scholar
• Kambeitz J, Kambeitz-Ilankovic L, Leucht S, Wood S, Davatzikos C, Malchow B, Falkai P, Koutsouleris N. 2015. Detecting neuroimaging biomarkers for schizophrenia: a meta-analysis of multivariate pattern recognition studies. Neuropsychopharmacol. 40:1742–1751.
   PubMed Web of Science ®Google Scholar
• Kamis D, Stratton L, Calvo M, Padilla E, Florenzano N, Guerrero G, Molina Rangeon B, Molina J, de Erausquin GA. 2015. Sex and laterality differences in parkinsonian impairment and transcranial ultrasound in never-treated schizophrenics and their first degree relatives in an Andean population. Schizophr Res. 164:250–255.
   PubMed Web of Science ®Google Scholar
• Kang C, Yang X, Xu X, Liu H, Su P, Yang J. 2012. Association study of neuregulin 1 gene polymorphisms with auditory P300 in schizophrenia. Am J Med Genet B Neuropsychiatr Genet. 159B:422–428.
   PubMed Web of Science ®Google Scholar
• Kasper S, Tauscher J, Willeit M, Stamenkovic M, Neumeister A, Kufferle B, Barnas C, Stastny J, Praschak-Rieder N, Pezawas L, et al. 2002. Receptor and transporter imaging studies in schizophrenia, depression, bulimia and Tourette's disorder-implications for psychopharmacology. World J Biol Psychiatry. 3:133–146.
   PubMedGoogle Scholar
• Kegeles LS, Mao X, Stanford AD, Girgis R, Ojeil N, Xu X, Gil R, Slifstein M, Abi-Dargham A, Lisanby SH, et al. 2012. Elevated prefrontal cortex γ-aminobutyric acid and glutamate-glutamine levels in schizophrenia measured in vivo with proton magnetic resonance spectroscopy. Arch Gen Psychiatry. 69:449–459.
   PubMed Web of Science ®Google Scholar
• Kegeles LS, Slifstein M, Xu X, Urban N, Thompson JL, Moadel T, Harkavy-Friedman JM, Gil R, Laruelle M, Abi-Dargham A. 2010. Striatal and extrastriatal dopamine D2/D3 receptors in schizophrenia evaluated with [18F]fallypride positron emission tomography. Biol Psychiatry. 68:634–641.
   PubMed Web of Science ®Google Scholar
• Kendler KS. 2015. A joint history of the nature of genetic variation and the nature of schizophrenia. Mol Psychiatry. 20:77–83.
   PubMed Web of Science ®Google Scholar
• Kessler RM, Woodward ND, Riccardi P, Li R, Ansari MS, Anderson S, Dawant B, Zald D, Meltzer HY. 2009. Dopamine D2 receptor levels in striatum, thalamus, substantia nigra, limbic regions, and cortex in schizophrenic subjects. Biol Psychiatry. 65:1024–1031.
   PubMed Web of Science ®Google Scholar
• Kim JH, Park BL, Pasaje CF, Bae JS, Park CS, Cha B, Kim BJ, Lee M, Choi WH, Shin TM, et al. 2012. Lack of associations of neuregulin 1 variations with schizophrenia and smooth pursuit eye movement abnormality in a Korean population. J Mol Neurosci. 46:476–482.
   PubMed Web of Science ®Google Scholar
• Kirov G, Grozeva D, Norton N, Ivanov D, Mantripragada KK, Holmans P, International Schizophrenia Consortium, Wellcome Trust Case Control Consortium, Craddock N, Owen MJ, et al. 2009a. Support for the involvement of large copy number variants in the pathogenesis of schizophrenia. Hum Mol Genet. 18:1497–1503.
   PubMed Web of Science ®Google Scholar
• Kirov G, Gumus D, Chen W, Norton N, Georgieva L, Sari M, O’Donovan MC, Erdogan F, Owen MJ, Ropers HH, et al. 2008. Comparative genome hybridization suggests a role for NRXN1 and APBA2 in schizophrenia. Hum Mol Genet. 17:458–465.
   PubMed Web of Science ®Google Scholar
• Kirov G, Pocklington AJ, Holmans P, Ivanov D, Ikeda M, Ruderfer D, Moran J, Chambert K, Toncheva D, Georgieva L, et al. 2012. De novo CNV analysis implicates specific abnormalities of postsynaptic signalling complexes in the pathogenesis of schizophrenia. Mol Psychiatry. 17:142–153.
   PubMed Web of Science ®Google Scholar
• Kirov G, Rujescu D, Ingason A, Collier DA, O’Donovan MC, Owen MJ. 2009b. Neurexin 1 (NRXN1) deletions in schizophrenia. Schizophr Bull 35(5):851–854.
   PubMed Web of Science ®Google Scholar
• Knott V, Millar A, Fisher D, Albert P. 2010. Effects of nicotine on the amplitude and gating of the auditory P50 and its influence by dopamine D2 receptor gene polymorphism. Neuroscience. 166:145–156.
   PubMed Web of Science ®Google Scholar
• Kornhuber J, Mack-Burkhardt F, Riederer P, Hebenstreit GF, Reynolds GP, Andrews HB, Beckmann H. 1989. [3H]MK-801 binding sites in postmortem brain regions of schizophrenic patients. J Neural Transm. 77:231–236.
   PubMed Web of Science ®Google Scholar
• Kumakura Y, Cumming P, Vernaleken I, Buchholz HG, Siessmeier T, Heinz A, Kienast T, Bartenstein P, Grunder G. 2007. Elevated [18F]fluorodopamine turnover in brain of patients with schizophrenia: an [18F]fluorodopa/positron emission tomography study. J Neurosci. 27:8080–8087.
   PubMed Web of Science ®Google Scholar
• Laakso A, Bergman J, Haaparanta M, Vilkman H, Solin O, Syvalahti E, Hietala J. 2001. Decreased striatal dopamine transporter binding in vivo in chronic schizophrenia. Schizophr Res. 52:115–120.
   PubMed Web of Science ®Google Scholar
• Laakso A, Vilkman H, Alakare B, Haaparanta M, Bergman J, Solin O, Peurasaari J, Rakkolainen V, Syvalahti E, Hietala J. 2000. Striatal dopamine transporter binding in neuroleptic-naive patients with schizophrenia studied with positron emission tomography. Am J Psychiatry. 157:269–271.
   PubMed Web of Science ®Google Scholar
• Lambert M, Karow A, Leucht S, Schimmelmann BG, Naber D. 2010. Remission in schizophrenia: validity, frequency, predictors, and patients' perspective 5 years later. Dialogues Clin Neurosci. 12:393–407.
   PubMedGoogle Scholar
• Laruelle M, Abi-Dargham A, van Dyck CH, Gil R, D’Souza CD, Erdos J, McCance E, Rosenblatt W, Fingado C, Zoghbi SS, et al. 1996. Single photon emission computerized tomography imaging of amphetamine-induced dopamine release in drug-free schizophrenic subjects. Proc Natl Acad Sci USA. 93:9235–9240.
   PubMed Web of Science ®Google Scholar
• Lee KJ, Lee JS, Kim SJ, Correll CU, Wee H, Yoo SY, Jeong JM, Lee DS, Lee SI, Kwon JS. 2008. Loss of asymmetry in D2 receptors of putamen in unaffected family members at increased genetic risk for schizophrenia. Acta Psychiatr Scand. 118:200–208.
   PubMed Web of Science ®Google Scholar
• Lee KW, Woon PS, Teo YY, Sim K. 2012a. Genome wide association studies (GWAS) and copy number variation (CNV) studies of the major psychoses: what have we learnt? Neurosci Biobehav Rev. 36:556–571.
   PubMed Web of Science ®Google Scholar
• Lee SH, DeCandia TR, Ripke S, Yang J, Schizophrenia Psychiatric Genome-Wide Association Study Consortium, International Schizophrenia Consortium, Molecular Genetics of Schizophrenia Collaboration, Sullivan PF, Goddard ME, Keller MC, et al. 2012b. Estimating the proportion of variation in susceptibility to schizophrenia captured by common SNPs. Nat Genet. 44:247–250.
   PubMed Web of Science ®Google Scholar
• Lees J, Applegate E, Emsley R, Lewis S, Michalopoulou P, Collier T, Lopez-Lopez C, Kapur S, Pandina GJ, Drake RJ. 2015. Calibration and cross-validation of MCCB and CogState in schizophrenia. Psychopharmacology (Berl). 232:3873–3882.
   PubMed Web of Science ®Google Scholar
• Lencz T, Morgan TV, Athanasiou M, Dain B, Reed CR, Kane JM, Kucherlapati R, Malhotra AK. 2007. Converging evidence for a pseudoautosomal cytokine receptor gene locus in schizophrenia. Mol Psychiatry. 12:572–580.
   PubMed Web of Science ®Google Scholar
• Leonard S, Freedman R. 2006. Genetics of chromosome 15q13-q14 in schizophrenia. Biol Psychiatry. 60:115–122.
   PubMed Web of Science ®Google Scholar
• Lepage M, Bodnar M, Bowie CR. 2014. Neurocognition: clinical and functional outcomes in schizophrenia. Can J Psychiatry. 59:5–12.
   PubMed Web of Science ®Google Scholar
• Levinson DF, Duan J, Oh S, Wang K, Sanders AR, Shi J, Zhang N, Mowry BJ, Olincy A, Amin F, et al. 2011. Copy number variants in schizophrenia: confirmation of five previous findings and new evidence for 3q29 microdeletions and VIPR2 duplications. Am J Psychiatry. 168:302–316.
   PubMed Web of Science ®Google Scholar
• Lichtenstein P, Bjork C, Hultman CM, Scolnick E, Sklar P, Sullivan PF. 2006. Recurrence risks for schizophrenia in a Swedish national cohort. Psychol Med. 36:1417–1425.
   PubMed Web of Science ®Google Scholar
• Lichtenstein P, Yip BH, Bjork C, Pawitan Y, Cannon TD, Sullivan PF, Hultman CM. 2009. Common genetic determinants of schizophrenia and bipolar disorder in Swedish families: a population-based study. Lancet. 373:234–239.
   PubMed Web of Science ®Google Scholar
• Liddle EB, Bates AT, Das D, White TP, Groom MJ, Jansen M, Jackson GM, Hollis C, Liddle PF. 2013. Inefficient cerebral recruitment as a vulnerability marker for schizophrenia. Psychol Med. 43:169–182.
   PubMed Web of Science ®Google Scholar
• Light GA, Geyer MA, Clementz BA, Cadenhead KS, Braff DL. 2000. Normal P50 suppression in schizophrenia patients treated with atypical antipsychotic medications. Am J Psychiatry. 157:767–771.
   PubMed Web of Science ®Google Scholar
• Light GA, Swerdlow NR, Rissling AJ, Radant A, Sugar CA, Sprock J, Pela M, Geyer MA, Braff DL. 2012. Characterization of neurophysiologic and neurocognitive biomarkers for use in genomic and clinical outcome studies of schizophrenia. PLoS One. 7:e39434.
   PubMed Web of Science ®Google Scholar
• Lindstrom LH, Gefvert O, Hagberg G, Lundberg T, Bergstrom M, Hartvig P, Langstrom B. 1999. Increased dopamine synthesis rate in medial prefrontal cortex and striatum in schizophrenia indicated by L-(beta-11C) DOPA and PET. Biol Psychiatry. 46:681–688.
   PubMed Web of Science ®Google Scholar
• Liu X, Hong X, Chan RC, Kong F, Peng Z, Wan X, Wang C, Cheng L. 2013. Association study of polymorphisms in the alpha 7 nicotinic acetylcholine receptor subunit and catechol-o-methyl transferase genes with sensory gating in first-episode schizophrenia. Psychiatry Res. 209:431–438.
   PubMed Web of Science ®Google Scholar
• Louchart-de la Chapelle S, Nkam I, Houy E, Belmont A, Menard JF, Roussignol AC, Siwek O, Mezerai M, Guillermou M, Fouldrin G, et al. 2005. A concordance study of three electrophysiological measures in schizophrenia. Am J Psychiatry. 162:466–474.
   PubMed Web of Science ®Google Scholar
• Lu BY, Martin KE, Edgar JC, Smith AK, Lewis SF, Escamilla MA, Miller GA, Canive JM. 2007. Effect of catechol O-methyltransferase val(158)met polymorphism on the p50 gating endophenotype in schizophrenia. Biol Psychiatry. 62:822–825.
   PubMed Web of Science ®Google Scholar
• MacDonald AW, 3rd, Thermenos HW, Barch DM, Seidman LJ. 2009. Imaging genetic liability to schizophrenia: systematic review of FMRI studies of patients’ nonpsychotic relatives. Schizophr. Bull. 35:1142–1162.
   Google Scholar
• Marengo J. 1994. Classifying the courses of schizophrenia. Schizophr Bull. 20:519–536.
   PubMed Web of Science ®Google Scholar
• Marsman A, Mandl RC, Klomp DW, Bohlken MM, Boer VO, Andreychenko A, Cahn W, Kahn RS, Luijten PR, Hulshoff Pol HE. 2014. GABA and glutamate in schizophrenia: a 7 T ¹H-MRS study. Neuroimage Clin. 6:398–407.
   PubMed Web of Science ®Google Scholar
• Martin AK, Mowry B. 2015. Increased rare duplication burden genomewide in patients with treatment-resistant schizophrenia. Psychol Med. 46:469–476.
   PubMed Web of Science ®Google Scholar
• Martin AK, Robinson G, Reutens D, Mowry B. 2014. Cannabis abuse and age at onset in schizophrenia patients with large, rare copy number variants. Schizophr Res. 155:21–25.
   PubMed Web of Science ®Google Scholar
• Matsukawa N, Murai T. 2013. [Neuroimaging studies of social cognition in schizophrenia]. Nippon Rinsho. 71:615–618.
   PubMedGoogle Scholar
• Matsuzawa D, Obata T, Shirayama Y, Nonaka H, Kanazawa Y, Yoshitome E, Takanashi J, Matsuda T, Shimizu E, Ikehira H, et al. 2008. Negative correlation between brain glutathione level and negative symptoms in schizophrenia: a 3T 1H-MRS study. PLoS One. 3:e1944.
   PubMed Web of Science ®Google Scholar
• McCarthy SE, Gillis J, Kramer M, Lihm J, Yoon S, Berstein Y, Mistry M, Pavlidis P, Solomon R, Ghiban E, et al. 2014. De novo mutations in schizophrenia implicate chromatin remodeling and support a genetic overlap with autism and intellectual disability. Mol Psychiatry. 19:652–658.
   PubMed Web of Science ®Google Scholar
• McCarthy SE, Makarov V, Kirov G, Addington AM, McClellan J, Yoon S, Perkins DO, Dickel DE, Kusenda M, Krastoshevsky O, et al. 2009. Microduplications of 16p11.2 are associated with schizophrenia. Nat Genet. 41:1223–1227.
   PubMed Web of Science ®Google Scholar
• McGowan S, Lawrence AD, Sales T, Quested D, Grasby P. 2004. Presynaptic dopaminergic dysfunction in schizophrenia: a positron emission tomographic [18F]fluorodopa study. Arch Gen Psychiatry. 61:134–142.
   PubMed Web of Science ®Google Scholar
• Meyer-Lindenberg A, Miletich RS, Kohn PD, Esposito G, Carson RE, Quarantelli M, Weinberger DR, Berman KF. 2002. Reduced prefrontal activity predicts exaggerated striatal dopaminergic function in schizophrenia. Nat Neurosci. 5:267–271.
   PubMed Web of Science ®Google Scholar
• Millar A, Smith D, Choueiry J, Fisher D, Albert P, Knott V. 2011. The moderating role of the dopamine transporter 1 gene on P50 sensory gating and its modulation by nicotine. Neuroscience. 180:148–156.
   PubMed Web of Science ®Google Scholar
• Minzenberg MJ, Laird AR, Thelen S, Carter CS, Glahn DC. 2009. Meta-analysis of 41 functional neuroimaging studies of executive function in schizophrenia. Arch Gen Psychiatry. 66:811–822.
   PubMed Web of Science ®Google Scholar
• Mizrahi R, Addington J, Rusjan PM, Suridjan I, Ng A, Boileau I, Pruessner JC, Remington G, Houle S, Wilson AA. 2012. Increased stress-induced dopamine release in psychosis. Biol Psychiatry. 71:561–567.
   PubMed Web of Science ®Google Scholar
• Moreno-De-Luca D, Consortium S, Mulle JG, Simons Simplex Collection Genetics C., Kaminsky EB, Sanders SJ, Gene Star, Myers SM, Adam MP, Pakula AT et al. 2010. Deletion 17q12 is a recurrent copy number variant that confers high risk of autism and schizophrenia. Am J Hum Genet. 87:618–630.
   PubMed Web of Science ®Google Scholar
• Mourao-Miranda J, Almeida JR, Hassel S, de Oliveira L, Versace A, Marquand AF, Sato JR, Brammer M, Phillips ML. 2012. Pattern recognition analyses of brain activation elicited by happy and neutral faces in unipolar and bipolar depression. Bipolar Disord. 14:451–460.
   PubMed Web of Science ®Google Scholar
• Mueller S, Keeser D, Reiser MF, Teipel S, Meindl T. 2012. Functional and structural MR imaging in neuropsychiatric disorders, part 2: application in schizophrenia and autism. AJNR Am J Neuroradiol. 33:2033–2037.
   PubMed Web of Science ®Google Scholar
• Mukherjee J, Christian BT, Dunigan KA, Shi B, Narayanan TK, Satter M, Mantil J. 2002. Brain imaging of 18F-fallypride in normal volunteers: blood analysis, distribution, test-retest studies, and preliminary assessment of sensitivity to aging effects on dopamine D-2/D-3 receptors. Synapse. 46:170–188.
   PubMed Web of Science ®Google Scholar
• Mulle JG, Dodd AF, McGrath JA, Wolyniec PS, Mitchell AA, Shetty AC, Sobreira NL, Valle D, Rudd MK, Satten G, et al. 2010. Microdeletions of 3q29 confer high risk for schizophrenia. Am J Hum Genet. 87:229–236.
   PubMed Web of Science ®Google Scholar
• Mulle JG, Pulver AE, McGrath JA, Wolyniec PS, Dodd AF, Cutler DJ, Sebat J, Malhotra D, Nestadt G, Conrad DF, et al. 2014. Reciprocal duplication of the Williams-Beuren syndrome deletion on chromosome 7q11.23 is associated with schizophrenia. Biol Psychiatry. 75:371–377.
   PubMed Web of Science ®Google Scholar
• Nuechterlein KH, Barch DM, Gold JM, Goldberg TE, Green MF, Heaton RK. 2004. Identification of separable cognitive factors in schizophrenia. Schizophr Res. 72:29–39.
   PubMed Web of Science ®Google Scholar
• Nuechterlein KH, Green MF, Calkins ME, Greenwood TA, Gur RE, Gur RC, Lazzeroni LC, Light GA, Radant AD, Seidman LJ, et al. 2015. Attention/vigilance in schizophrenia: performance results from a large multi-site study of the Consortium on the Genetics of Schizophrenia (COGS). Schizophr Res. 163:38–46.
   PubMed Web of Science ®Google Scholar
• O’Donovan MC, Craddock N, Norton N, Williams H, Peirce T, Moskvina V, Nikolov I, Hamshere M, Carroll L, Georgieva L, et al. 2008. Identification of loci associated with schizophrenia by genome-wide association and follow-up. Nat Genet. 40:1053–1055.
   PubMed Web of Science ®Google Scholar
• Olincy A, Braff DL, Adler LE, Cadenhead KS, Calkins ME, Dobie DJ, Green MF, Greenwood TA, Gur RE, Gur RC, et al. 2010. Inhibition of the P50 cerebral evoked response to repeated auditory stimuli: results from the Consortium on Genetics of Schizophrenia. Schizophr Res. 119:175–182.
   PubMed Web of Science ®Google Scholar
• Ota M, Sato N, Ishikawa M, Hori H, Sasayama D, Hattori K, Teraishi T, Obu S, Nakata Y, Nemoto K, et al. 2012. Discrimination of female schizophrenia patients from healthy women using multiple structural brain measures obtained with voxel-based morphometry. Psychiatry Clin Neurosci. 66:611–617.
   PubMed Web of Science ®Google Scholar
• Ozomaro U, Wahlestedt C, Nemeroff CB. 2013. Personalized medicine in psychiatry: problems and promises. BMC Med. 11:132.
   PubMed Web of Science ®Google Scholar
• Park BL, Shin HD, Cheong HS, Park CS, Sohn JW, Kim BJ, Seo HK, Kim JW, Kim KH, Shin TM, et al. 2009. Association analysis of COMT polymorphisms with schizophrenia and smooth pursuit eye movement abnormality. J Hum Genet. 54:709–712.
   PubMed Web of Science ®Google Scholar
• Pietrzak RH, Olver J, Norman T, Piskulic D, Maruff P, Snyder PJ. 2009. A comparison of the CogState Schizophrenia Battery and the Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) Battery in assessing cognitive impairment in chronic schizophrenia. J Clin Exp Neuropsychol. 31:848–859.
   PubMed Web of Science ®Google Scholar
• Plitman E, de la Fuente-Sandoval C, Reyes-Madrigal F, Chavez S, Gomez-Cruz G, Leon-Ortiz P, Graff-Guerrero A. 2015. Elevated Myo-Inositol, Choline, and Glutamate Levels in the Associative Striatum of Antipsychotic-Naive Patients With First-Episode Psychosis: A Proton Magnetic Resonance Spectroscopy Study With Implications for Glial Dysfunction. Schizophr Bull. 42:415–424.
   PubMed Web of Science ®Google Scholar
• Poels EM, Kegeles LS, Kantrowitz JT, Javitt DC, Lieberman JA, Abi-Dargham A, Girgis RR. 2014a. Glutamatergic abnormalities in schizophrenia: a review of proton MRS findings. Schizophr Res. 152:325–332.
   PubMed Web of Science ®Google Scholar
• Poels EM, Kegeles LS, Kantrowitz JT, Slifstein M, Javitt DC, Lieberman JA, Abi-Dargham A, Girgis RR. 2014b. Imaging glutamate in schizophrenia: review of findings and implications for drug discovery. Mol Psychiatry. 19:20–29.
   PubMed Web of Science ®Google Scholar
• Porteous DJ, Thomson PA, Millar JK, Evans KL, Hennah W, Soares DC, McCarthy S, McCombie WR, Clapcote SJ, Korth C, et al. 2014. DISC1 as a genetic risk factor for schizophrenia and related major mental illness: response to Sullivan. Mol Psychiatry. 19:141–143.
   PubMed Web of Science ®Google Scholar
• Purcell SM, Moran JL, Fromer M, Ruderfer D, Solovieff N, Roussos P, O’Dushlaine C, Chambert K, Bergen SE, Kahler A, et al. 2014. A polygenic burden of rare disruptive mutations in schizophrenia. Nature. 506:185–190.
   PubMed Web of Science ®Google Scholar
• Quednow BB, Brinkmeyer J, Mobascher A, Nothnagel M, Musso F, Grunder G, Savary N, Petrovsky N, Frommann I, Lennertz L, et al. 2012. Schizophrenia risk polymorphisms in the TCF4 gene interact with smoking in the modulation of auditory sensory gating. Proc Natl Acad Sci USA. 109:6271–6276.
   PubMed Web of Science ®Google Scholar
• Randall AD, Kurihara M, Brandon NJ, Brown JT. 2014. Disrupted in schizophrenia 1 and synaptic function in the mammalian central nervous system. Eur J Neurosci. 39:1068–1073.
   PubMed Web of Science ®Google Scholar
• Rasmussen H, Erritzoe D, Andersen R, Ebdrup BH, Aggernaes B, Oranje B, Kalbitzer J, Madsen J, Pinborg LH, Baare W, et al. 2010. Decreased frontal serotonin2A receptor binding in antipsychotic-naive patients with first-episode schizophrenia. Arch Gen Psychiatry. 67:9–16.
   PubMed Web of Science ®Google Scholar
• Raux G, Bumsel E, Hecketsweiler B, van Amelsvoort T, Zinkstok J, Manouvrier-Hanu S, Fantini C, Breviere GM, Di Rosa G, Pustorino G, et al. 2007. Involvement of hyperprolinemia in cognitive and psychiatric features of the 22q11 deletion syndrome. Hum Mol Genet. 16:83–91.
   PubMed Web of Science ®Google Scholar
• Redlich R, Almeida JJ, Grotegerd D, Opel N, Kugel H, Heindel W, Arolt V, Phillips ML, Dannlowski U. 2014. Brain morphometric biomarkers distinguishing unipolar and bipolar depression. A voxel-based morphometry-pattern classification approach. JAMA Psychiatry. 71:1222–1230.
   PubMed Web of Science ®Google Scholar
• Rees E, Walters JT, Chambert KD, O’Dushlaine C, Szatkiewicz J, Richards AL, Georgieva L, Mahoney-Davies G, Legge SE, Moran JL, et al. 2014a. CNV analysis in a large schizophrenia sample implicates deletions at 16p12.1 and SLC1A1 and duplications at 1p36.33 and CGNL1. Hum Mol Genet. 23:1669–1676.
   PubMed Web of Science ®Google Scholar
• Rees E, Walters JT, Georgieva L, Isles AR, Chambert KD, Richards AL, Mahoney-Davies G, Legge SE, Moran JL, McCarroll SA, et al. 2014b. Analysis of copy number variations at 15 schizophrenia-associated loci. Brit J Psychiatry. 204:108–114.
   PubMed Web of Science ®Google Scholar
• Reichenberg A, Harvey PD. 2007. Neuropsychological impairments in schizophrenia: Integration of performance-based and brain imaging findings. Psychol Bull. 133:833–858.
   PubMed Web of Science ®Google Scholar
• Reilly JL, Sweeney JA. 2014. Generalized and specific neurocognitive deficits in psychotic disorders: utility for evaluating pharmacological treatment effects and as intermediate phenotypes for gene discovery. Schizophr Bull. 40:516–522.
   PubMed Web of Science ®Google Scholar
• Ripke S, O’Dushlaine C, Chambert K, Moran JL, Kahler AK, Akterin S, Bergen SE, Collins AL, Crowley JJ, Fromer M, et al. 2013. Genome-wide association analysis identifies 13 new risk loci for schizophrenia. Nat Genet. 45:1150–1159.
   PubMed Web of Science ®Google Scholar
• Rujescu D, Ingason A, Cichon S, Pietilainen OP, Barnes MR, Toulopoulou T, Picchioni M, Vassos E, Ettinger U, Bramon E, et al. 2009. Disruption of the neurexin 1 gene is associated with schizophrenia. Hum Mol Genet. 18:988–996.
   PubMed Web of Science ®Google Scholar
• Rybakowski JK, Borkowska A, Czerski PM, Hauser J. 2002. Eye movement disturbances in schizophrenia and a polymorphism of catechol-O-methyltransferase gene. Psychiatry Res. 113:49–57.
   PubMed Web of Science ®Google Scholar
• Salavati B, Rajji TK, Price R, Sun Y, Graff-Guerrero A, Daskalakis ZJ. 2015. Imaging-based neurochemistry in schizophrenia: a systematic review and implications for dysfunctional long-term potentiation. Schizophr Bull. 41:44–56.
   PubMed Web of Science ®Google Scholar
• Saoud M, d’Amato T, Gutknecht C, Triboulet P, Bertaud JP, Marie-Cardine M, Dalery J, Rochet T. 2000. Neuropsychological deficit in siblings discordant for schizophrenia. Schizophr Bull. 26:893–902.
   PubMed Web of Science ®Google Scholar
• Schaefer J, Giangrande E, Weinberger DR, Dickinson D. 2013. The global cognitive impairment in schizophrenia: consistent over decades and around the world. Schizophr Res. 150:42–50.
   PubMed Web of Science ®Google Scholar
• Schizophrenia Working Group of the Psychiatric Genomics Consortium. 2014. Biological insights from 108 schizophrenia-associated genetic loci. Nature. 511:421–427.
   PubMed Web of Science ®Google Scholar
• Schmechtig A, Vassos E, Kumari V, Hutton SB, Collier DA, Morris RG, Williams SC, Ettinger U. 2010. Association of Neuregulin 1 rs3924999 genotype with antisaccades and smooth pursuit eye movements. Genes Brain Behav. 9:621–627.
   PubMed Web of Science ®Google Scholar
• Schmidt SJ, Mueller DR, Roder V. 2011. Social cognition as a mediator variable between neurocognition and functional outcome in schizophrenia: empirical review and new results by structural equation modeling. Schizophr. Bull. 37:S41–S54.
   Google Scholar
• Schnack HG, Nieuwenhuis M, van Haren NE, Abramovic L, Scheewe TW, Brouwer RM, Hulshoff Pol HE, Kahn RS. 2014. Can structural MRI aid in clinical classification? A machine learning study in two independent samples of patients with schizophrenia, bipolar disorder and healthy subjects. Neuroimage. 84:299–306.
   PubMed Web of Science ®Google Scholar
• Schneider M, Debbane M, Bassett AS, Chow EW, Fung WL, van den Bree M, Owen M, Murphy KC, Niarchou M, Kates WR, et al. 2014. Psychiatric disorders from childhood to adulthood in 22q11.2 deletion syndrome: results from the International Consortium on Brain and Behavior in 22q11.2 Deletion Syndrome. Am J Psychiatry. 171:627–639.
   PubMed Web of Science ®Google Scholar
• Sendt KV, Tracy DK, Bhattacharyya S. 2015. A systematic review of factors influencing adherence to antipsychotic medication in schizophrenia-spectrum disorders. Psychiatry Res. 225:14–30.
   PubMed Web of Science ®Google Scholar
• Sepede G, Ferretti A, Perrucci MG, Gambi F, Di Donato F, Nuccetelli F, Del Gratta C, Tartaro A, Salerno RM, Ferro FM, et al. 2010. Altered brain response without behavioral attention deficits in healthy siblings of schizophrenic patients: an event-related fMRI study. NeuroImage. 49:1080–1090.
   PubMed Web of Science ®Google Scholar
• Serpa MH, Ou Y, Schaufelberger MS, Doshi J, Ferreira LK, Machado-Vieira R, Menezes PR, Scazufca M, Davatzikos C, Busatto GF, et al. 2014. Neuroanatomical classification in a population-based sample of psychotic major depression and bipolar I disorder with 1 year of diagnostic stability. Biomed Res Int. 2014:706157.
   PubMed Web of Science ®Google Scholar
• Shaikh M, Hall MH, Schulze K, Dutt A, Walshe M, Williams I, Constante M, Picchioni M, Toulopoulou T, Collier D, et al. 2011. Do COMT, BDNF and NRG1 polymorphisms influence P50 sensory gating in psychosis? Psychol Med. 41:263–276.
   PubMed Web of Science ®Google Scholar
• Shi J, Levinson DF, Duan J, Sanders AR, Zheng Y, Pe’er I, Dudbridge F, Holmans PA, Whittemore AS, Mowry BJ, et al. 2009. Common variants on chromosome 6p22.1 are associated with schizophrenia. Nature. 460:753–757.
   PubMed Web of Science ®Google Scholar
• Shin HD, Park BL, Bae JS, Park TJ, Chun JY, Park CS, Sohn JW, Kim BJ, Kang YH, Kim JW, et al. 2010. Association of ZDHHC8 polymorphisms with smooth pursuit eye movement abnormality. Am J Med Genet B Neuropsychiatr Genet. 153B:1167–1172.
   PubMed Web of Science ®Google Scholar
• Shprintzen RJ, Goldberg R, Golding-Kushner KJ, Marion RW. 1992. Late-onset psychosis in the velo-cardio-facial syndrome. Am J Med Genet. 42:141–142.
   PubMed Web of Science ®Google Scholar
• Smesny S, Gussew A, Biesel NJ, Schack S, Walther M, Rzanny R, Milleit B, Gaser C, Sobanski T, Schultz CC, et al. 2015. Glutamatergic dysfunction linked to energy and membrane lipid metabolism in frontal and anterior cingulate cortices of never treated first-episode schizophrenia patients. Schizophr Res. 168:322–329.
   PubMed Web of Science ®Google Scholar
• Sommer IE, Kahn RS. 2015. The contribution of neuroimaging to understanding schizophrenia; past, present, and future. Schizophr Bull. 41:1–3.
   PubMed Web of Science ®Google Scholar
• Squarcione C, Torti MC, Di Fabio F, Biondi M. 2013. 22q11 deletion syndrome: a review of the neuropsychiatric features and their neurobiological basis. Neuropsychiatr Dis Treat. 9:1873–1884.
   PubMed Web of Science ®Google Scholar
• St Clair D, Blackwood D, Muir W, Carothers A, Walker M, Spowart G, Gosden C, Evans HJ. 1990. Association within a family of a balanced autosomal translocation with major mental illness. Lancet. 336:13–16.
   PubMed Web of Science ®Google Scholar
• Stefanis NC, Van Os J, Avramopoulos D, Smyrnis N, Evdokimidis I, Hantoumi I, Stefanis CN. 2004. Variation in catechol-o-methyltransferase val158 met genotype associated with schizotypy but not cognition: a population study in 543 young men. Biol Psychiatry. 56:510–515.
   PubMed Web of Science ®Google Scholar
• Stefansson H, Ophoff RA, Steinberg S, Andreassen OA, Cichon S, Rujescu D, Werge T, Pietilainen OP, Mors O, Mortensen PB, et al. 2009. Common variants conferring risk of schizophrenia. Nature. 460:744–747.
   PubMed Web of Science ®Google Scholar
• Stefansson H, Rujescu D, Cichon S, Pietilainen OP, Ingason A, Steinberg S, Fossdal R, Sigurdsson E, Sigmundsson T, Buizer-Voskamp JE, et al. 2008. Large recurrent microdeletions associated with schizophrenia. Nature. 455:232–236.
   PubMed Web of Science ®Google Scholar
• Steinberg S, de Jong S, Mattheisen M, Costas J, Demontis D, Jamain S, Pietilainen OP, Lin K, Papiol S, Huttenlocher J, et al. 2014. Common variant at 16p11.2 conferring risk of psychosis. Mol Psychiatry. 19:108–114.
   PubMed Web of Science ®Google Scholar
• Stöber G, Ben-Shachar D, Cardon M, Falkai P, Fonteh AN, Gawlik M, Glenthoj BY, Grünblatt E, Jablensky A, Kim YK, et al. 2009. Schizophrenia: from the brain to peripheral markers. A consensus paper of the WFSBP task force on biological markers. World J Biol Psychiatry. 10:127–155.
   PubMed Web of Science ®Google Scholar
• Suhara T, Okubo Y, Yasuno F, Sudo Y, Inoue M, Ichimiya T, Nakashima Y, Nakayama K, Tanada S, Suzuki K, et al. 2002. Decreased dopamine D2 receptor binding in the anterior cingulate cortex in schizophrenia. Arch Gen Psychiatry. 59:25–30.
   PubMed Web of Science ®Google Scholar
• Sullivan PF, Kendler KS, Neale MC. 2003. Schizophrenia as a complex trait: evidence from a meta-analysis of twin studies. Arch Gen Psychiatry. 60:1187–1192.
   PubMed Web of Science ®Google Scholar
• Sullivan PF, Lin D, Tzeng JY, van den Oord E, Perkins D, Stroup TS, Wagner M, Lee S, Wright FA, Zou F, et al. 2008. Genomewide association for schizophrenia in the CATIE study: results of stage 1. Mol Psychiatry. 13:570–584.
   PubMed Web of Science ®Google Scholar
• Suridjan I, Rusjan P, Addington J, Wilson AA, Houle S, Mizrahi R. 2013. Dopamine D2 and D3 binding in people at clinical high risk for schizophrenia, antipsychotic-naive patients and healthy controls while performing a cognitive task. J Psychiatry Neurosci. 38:98–106.
   PubMed Web of Science ®Google Scholar
• Swerdlow NR, Gur RE, Braff DL. 2015. Consortium on the Genetics of Schizophrenia (COGS) assessment of endophenotypes for schizophrenia: an introduction to this Special Issue of Schizophrenia Research. Schizophr Res. 163:9–16.
   PubMed Web of Science ®Google Scholar
• Takizawa R, Fukuda M, Kawasaki S, Kasai K, Mimura M, Pu S, Noda T, Niwa S, Okazaki Y, Joint Project for Psychiatric Application of Near-Infrared Spectroscopy Group. 2014. Neuroimaging-aided differential diagnosis of the depressive state. Neuroimage. 85:498–507.
   PubMed Web of Science ®Google Scholar
• Talvik M, Nordstrom AL, Okubo Y, Olsson H, Borg J, Halldin C, Farde L. 2006. Dopamine D2 receptor binding in drug-naïve patients with schizophrenia examined with raclopride-C11 and positron emission tomography. Psychiatry Res. 148:165–173.
   PubMed Web of Science ®Google Scholar
• Talvik M, Nordstrom AL, Olsson H, Halldin C, Farde L. 2003. Decreased thalamic D2/D3 receptor binding in drug-naive patients with schizophrenia: a PET study with [11C]FLB 457. Int J Neuropsychopharmacol. 6:361–370.
   PubMed Web of Science ®Google Scholar
• Tauscher J, Kapur S, Verhoeff NP, Hussey DF, Daskalakis ZJ, Tauscher-Wisniewski S, Wilson AA, Houle S, Kasper S, Zipursky RB. 2002. Brain serotonin 5-HT(1A) receptor binding in schizophrenia measured by positron emission tomography and [11C]WAY-100635. Arch Gen Psychiatry. 59:514–520.
   PubMed Web of Science ®Google Scholar
• Thibaut F. 2006. Schizophrenia: An example of complex genetic disease. World J Biol Psychiatry. 7:194–197.
   PubMed Web of Science ®Google Scholar
• Thibaut F, Boutros NN, Jarema M, Oranje B, Hasan A, Daskalakis ZJ, Wichniak A, Schmitt A, Riederer P, Falkai P, et al. 2015. Consensus paper of the WFSBP Task Force on Biological Markers: Criteria for biomarkers and endophenotypes of schizophrenia part I: Neurophysiology. World J Biol Psychiatry. 16:280–290.
   PubMed Web of Science ®Google Scholar
• Tsai GE, Lin PY. 2010. Strategies to enhance N-methyl-D-aspartate receptor-mediated neurotransmission in schizophrenia, a critical review and meta-analysis. Curr Pharm Design. 16:522–537.
   PubMed Web of Science ®Google Scholar
• Tsitsipa E, Fountoulakis KN. 2015. The neurocognitive functioning in bipolar disorder: a systematic review of data. Ann Gen Psychiatry. 14:42. doi:10.1186/s12991-015-0081-z
   PubMed Web of Science ®Google Scholar
• Vacic V, McCarthy S, Malhotra D, Murray F, Chou HH, Peoples A, Makarov V, Yoon S, Bhandari A, Corominas R, et al. 2011. Duplications of the neuropeptide receptor gene VIPR2 confer significant risk for schizophrenia. Nature. 471:499–503.
   PubMed Web of Science ®Google Scholar
• Vawter MP, Mamdani F, Macciardi F. 2011. An integrative functional genomics approach for discovering biomarkers in schizophrenia. Brief Funct Genomics. 10:387–399.
   PubMed Web of Science ®Google Scholar
• Ventura J, Thames AD, Wood RC, Guzik LH, Hellemann GS. 2010. Disorganization and reality distortion in schizophrenia: a meta-analysis of the relationship between positive symptoms and neurocognitive deficits. Schizophr Res. 121:1–14.
   PubMed Web of Science ®Google Scholar
• Verhoeff NP, Hussey D, Lee M, Tauscher J, Papatheodorou G, Wilson AA, Houle S, Kapur S. 2002. Dopamine depletion results in increased neostriatal D(2), but not D(1), receptor binding in humans. Mol Psychiatry. 7:233–238.
   PubMedGoogle Scholar
• Walsh T, McClellan JM, McCarthy SE, Addington AM, Pierce SB, Cooper GM, Nord AS, Kusenda M, Malhotra D, Bhandari A, et al. 2008. Rare structural variants disrupt multiple genes in neurodevelopmental pathways in schizophrenia. Science. 320:539–543.
   PubMed Web of Science ®Google Scholar
• Watt DC, Katz K, Shepherd M. 1983. The natural history of schizophrenia: a 5-year prospective follow-up of a representative sample of schizophrenics by means of a standardized clinical and social assessment. Psychol Med. 13:663–670.
   PubMed Web of Science ®Google Scholar
• Weinberger DR, Berman KF. 1988. Speculation on the meaning of cerebral metabolic hypofrontality in schizophrenia. Schizophr Bull. 14:157–168.
   PubMed Web of Science ®Google Scholar
• Wheeler AL, Voineskos AN. 2014. A review of structural neuroimaging in schizophrenia: from connectivity to connectomics. Front Hum Neurosci. 8:653. doi:10.3389/fnhum.2014.00653
   PubMed Web of Science ®Google Scholar
• Whitfield-Gabrieli S, Thermenos HW, Milanovic S, Tsuang MT, Faraone SV, McCarley RW, Shenton ME, Green AI, Nieto-Castanon A, LaViolette P, et al. 2009. Hyperactivity and hyperconnectivity of the default network in schizophrenia and in first-degree relatives of persons with schizophrenia. Proc Natl Acad Sci USA. 106:1279–1284.
   PubMed Web of Science ®Google Scholar
• WHO. 2010. International Statistical Classification of Diseases and Related Health Problems 10th Revision Geneva, Switzerland: WHO.
   Google Scholar
• Willeit M, Ginovart N, Kapur S, Houle S, Hussey D, Seeman P, Wilson AA. 2006. High-affinity states of human brain dopamine D2/3 receptors imaged by the agonist [11C]-(+)-PHNO. Biol Psychiatry. 59:389–394.
   PubMed Web of Science ®Google Scholar
• Wray NR, Gottesman II. 2012. Using summary data from the danish national registers to estimate heritabilities for schizophrenia, bipolar disorder, and major depressive disorder. Front Genet. 3:118. doi:10.3389/fgene.2012.00118
   PubMedGoogle Scholar
• Xu B, Ionita-Laza I, Roos JL, Boone B, Woodrick S, Sun Y, Levy S, Gogos JA, Karayiorgou M. 2012. De novo gene mutations highlight patterns of genetic and neural complexity in schizophrenia. Nat Genet. 44:1365–1369.
   PubMed Web of Science ®Google Scholar
• Xu B, Roos JL, Dexheimer P, Boone B, Plummer B, Levy S, Gogos JA, Karayiorgou M. 2011. Exome sequencing supports a de novo mutational paradigm for schizophrenia. Nat Genet. 43:864–868.
   PubMed Web of Science ®Google Scholar
• Xu B, Roos JL, Levy S, van Rensburg EJ, Gogos JA, Karayiorgou M. 2008. Strong association of de novo copy number mutations with sporadic schizophrenia. Nat Genet. 40:880–885.
   PubMed Web of Science ®Google Scholar
• Yasuno F, Suhara T, Okubo Y, Sudo Y, Inoue M, Ichimiya T, Takano A, Nakayama K, Halldin C, Farde L. 2004. Low dopamine d(2) receptor binding in subregions of the thalamus in schizophrenia. Am J Psychiatry. 161:1016–1022.
   PubMed Web of Science ®Google Scholar
• Yee CM, Nuechterlein KH, Morris SE, White PM. 1998. P50 suppression in recent-onset schizophrenia: clinical correlates and risperidone effects. J Abnorm Psychol. 107:691–698.
   PubMed Web of Science ®Google Scholar
• Yeo BT, Krienen FM, Sepulcre J, Sabuncu MR, Lashkari D, Hollinshead M, Roffman JL, Smoller JW, Zollei L, Polimeni JR, et al. 2011. The organization of the human cerebral cortex estimated by intrinsic functional connectivity. J Neurophysiol. 106:1125–1165.
   PubMed Web of Science ®Google Scholar
• Yeo RA, Gangestad SW, Liu J, Ehrlich S, Thoma RJ, Pommy J, Mayer AR, Schulz SC, Wassink TH, Morrow EM, et al. 2013. The impact of copy number deletions on general cognitive ability and ventricle size in patients with schizophrenia and healthy control subjects. Biol Psychiatry. 73:540–545.
   PubMed Web of Science ®Google Scholar
• Zhuo C, Zhu J, Qin W, Qu H, Ma X, Tian H, Xu Q, Yu C. 2014. Functional connectivity density alterations in schizophrenia. Front Behav Neurosci. 8:404. doi:10.3389/fnbeh.2014.00404
   PubMed Web of Science ®Google Scholar
• Zink M, Englisch S, Schmitt A. 2014. Antipsychotic treatment modulates glutamate transport and NMDA receptor expression. Eur Arch Psychiatry Clin Neurosci. 264:S67–S82.
   PubMed Web of Science ®Google Scholar